



TheraCryf plc

("TheraCryf", the "Company" or the "Group")

Marking World Mental Health Day and Q4 Conference Schedule Update

Alderley Park, 10 October 2025 - TheraCryf plc (AIM: TCF), the clinical stage drug development company focussing on brain disorders, notes that today is World Mental Health Day and also shares its conference schedule for Q4 2025.

World Mental Health Day

10 October is [World Mental Health Day](#), aiming to raise awareness of mental health issues around the world and to mobilize efforts in support of mental health. Globally, more than 1 billion people live with a mental health condition*, with anxiety and depression being the most common, according to the World Health Organization.

TheraCryf is honoured to be contributing to the potential treatment of mental disorders such as anxiety and addictive behaviour through its lead Ox-1 programme, a class-leading orexin-1 antagonist, targeting binge eating disorder and other substance use disorders.

TheraCryf's Chief Operating Officer, Dr Helen Kuhlman, discusses the potential of orexin-based treatments for addictive behaviours in her article *'The Promise of Orexin-1 Antagonists in Addiction Treatment'*, in the most recent edition of [European Biopharmaceutical Review](#).

*World Mental Health Today Report, September 2025

Q4 Conference Schedule

The TheraCryf leadership team will also be attending the following industry and investor conferences and events during Q4.

BioSeed North, 21 October 2025, Manchester

BioEurope, 3-5 November 2025, Vienna

ShareSoc Growth Company Seminar, 13 November 2025, London

Mello London, 18-19 November 2025, London

London Life Sciences Week & Jefferies Global Healthcare Conference, 17-21 November 2025, London

Dr Huw Jones, CEO of TheraCryf, said:

"As we mark World Mental Health Day, we are very much aware of the impact mental health conditions have on quality of life for sufferers and their families. We are on track with our work to enable our orexin-1 blocker to be used in clinical trials in under a year from now. The promise of these potential medicines is made very clear in the recent European Biopharma Review article and we look forward to reminding the industry and investors of the opportunity and plans for our lead programme during the upcoming conference season."

-Ends-

Enquiries

TheraCryf plc

Dr Huw Jones, CEO

Toni Hänninen, CFO

Dr Helen Kuhlman, COO

+44 (0)1625 315 090

enquiries@theracryf.com

Singer Capital Markets (NOMAD & Joint Broker)

Phil Davies / Oliver Platts / Patrick Weaver

+44 (0)20 7496 3000

Turner Pope Investments (Joint Broker)

James Pope / Andy Thacker

+44 (0)20 3657 0050

Vigo Consulting

Rozi Morris/ Melanie Toyne Sewell

+44 (0)20 7390 0230

theracryf@vigoconsulting.com

About TheraCryf plc

TheraCryf is the clinical stage drug development company focussing on brain disorders. The Company has a broad clinical and preclinical pipeline in indications including addiction, anxiety, fatigue, narcolepsy, glioblastoma* and neurodevelopmental disorders [*orphan indication].

The Company's strategy is to generate compelling data sets to preclinical and/or clinical proof of concept and partner its clinical programmes with mid-size to large pharma for larger trials and commercialisation. It also has a number of industry partnerships with companies, including Stalicia SA, in neurodevelopmental disorders. The Company has sourced know-how for programmes from companies such as Shire (now Takeda).

TheraCryf has worked with and has ongoing collaborations with major universities and hospitals such as the University of Manchester, La Sapienza (Università di Roma), the Erasmus Medical Centre, Rotterdam, Kings College London and the University of Michigan.

The Company has its headquarters and registered office at Alderley Park, Cheshire. It is quoted on AIM in London and trades under the ticker symbol TCF.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAUKVRRVOURRUA